Device Trial Radar · NCT07873892
Transarterial Embolization Versus Sham Procedure in Adults With Treatment-Resistant Inflammatory Arthritis of a Single Large Joint
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Dec 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- Istituto Ortopedico RizzoliAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AUSL Bologna
- First posted
- Oct 14, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn whether transarterial embolization (TAE) can relieve pain and improve well-being in adults with inflammatory arthritis that remains active in only one large joint (wrist, elbow, shoulder, ankle, knee or hip) despite anti-inflammatory drugs, joint injections and physiotherapy. The researchers expect that more people treated with TAE than with a sham (simulated) procedure will reach low pain and a good overall assessment of their health one month after the procedure. The main questions it aims to answer are: * Does TAE increase the proportion of participants who reach low pain and a good overall assessment of their health one month after the procedure, compared with a sham procedure? * Is TAE safe, and does it improve quality of life and reduce the need for medication over three months? TAE is a minimally invasive procedure. A thin catheter is guided through an artery in the groin or wrist to the small vessels that feed the inflamed lining of the joint, and tiny resorbable gelatin particles are injected to temporarily reduce the abnormal blood flow that sustains inflammation and pain. Researchers will compare TAE with a sham procedure to find out whether any benefit comes from the embolization itself rather than from the experience of undergoing a procedure. Participants will: * Be randomly assigned (like flipping a coin) to TAE or to the sham procedure. Neither the participants nor the doctor who evaluates them will know which procedure they received. * Undergo the procedure in the angiography room with light sedation. The sham procedure takes place in the same room, with the same team, sedation and duration, but without any puncture of the artery, contrast medium or X-rays. * Attend visits before the procedure and 1 week, 1 month and 3 months after it, answer questionnaires on pain and quality of life, and keep a diary of symptoms and medicines for 7 days after the procedure. After 3 months, participants who received the sham procedure will be offered TAE.
Conditions
- Arthritis
Interventions
Transarterial embolization with resorbable gelatin microspheresDevice
Superselective transarterial embolization of the arteries supplying the inflamed synovium of the target joint, using resorbable porcine gelatin microspheres (100-300 micrometres; CE-marked class III device) injected through a coaxial microcatheter until the pathological blush disappears. Ultrasound-guided femoral or radial access, light sedation with midazolam 2 mg IV and local anaesthesia. Single procedure.
Sham embolization procedureDevice
Simulated embolization procedure in the angiography suite with identical sedation (midazolam 2 mg IV), local anaesthesia and duration as the active procedure. Superficial subcutaneous puncture at the access site without arterial access, saline infusion and display of standardized angiographic sequences. No contrast medium, embolic agent or ionizing radiation. Single procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with pain VAS ≤15 mm and Patient Global Assessment ≤20 mm.Time frame: 1 month after the procedure.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.